drugset / Trial / NCT00319930
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.
Timeline
- Start
- 2005-05
- Primary completion
- —
- Completion
- 2007-05
Outcome
Outcome not reported
Stopped: “Discontinuation of program”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tanespimycin | Unknown | — | — |